Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568553 | 0.91 | GPR17 (0.43) | GPR17PTGER1PTGS2MRGPRX4DYRK1A | |
| SCHEMBL4568442 | 0.91 | MTNR1A (0.45) | GPR17MTNR1AMTNR1BPTGS2MRGPRX4 | |
| SCHEMBL4568567 | 0.90 | GPR17 (0.43) | GPR17PTGER1PTGS2MRGPRX4DYRK1A | |
| SCHEMBL4568557 | 0.86 | GPR17 (0.43) | GPR17MTNR1AMTNR1BPTGER1PTGS2 | |
| SCHEMBL4568213 | 0.84 | GPR17 (0.46) | GPR17PTGER1PTGS2MRGPRX4DYRK1A | |
| SCHEMBL4568598 | 0.84 | MRGPRX4 (0.42) | MTNR1AMTNR1BPTGER1MRGPRX4ENPP2 | |
| SCHEMBL3702535 | 0.84 | TUBB4A (0.48) | GPR17MTNR1AMTNR1BKDM4EGAA | |
| SCHEMBL3711072 | 0.83 | PTGER1 (0.41) | PTGER1 | |
| SCHEMBL3717010 | 0.83 | PTGER1 (0.46) | PTGER1MRGPRX4ENPP2 | |
| SCHEMBL3704461 | 0.83 | GPR17 (0.44) | GPR17MTNR1AMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | GPR17 59/4885MTNR1A 19/4885MTNR1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.